IORT for breast cancer boost keyvisual
Providing options for breast-conserving treatments. ZEISS IORT Solutions

TARGIT Boost Irradiation for Breast Cancer:

High effectiveness through targeted irradiation

Additional irradiation of the tumor bed (boost) is part of the standard of care in breast cancer therapy. In intraoperative radiotherapy the boost element of the external beam radiation therapy (EBRT) regime can be replaced and be administered to the target tissue immediately after wide local excision. This boost element of the overall treatment regime is highly accurate as it is applied at the time when the tumor bed is visualised during surgery. In two studies on the intraoperative boost with the INTRABEAM from ZEISS, compromising a total 450 patients, the five-year recidivism rate was a low 1.5 to 1.7 percent. This does not reflect select patients with a low recurrence rate.1,2

Comparison of EBRT and TARGIT Boost thumbnail
Comparison of EBRT and TARGIT Boost thumbnail

Main benefits:

  • Very low local recurrence rate.
  • Low rate of side effects.
  • Very good cosmetic result.

The intraoperative boost therapy is tolerated very well by patients. As studies on acute and long-term toxicity following the intraoperative boost (20 Gy) have shown, there are no conspicuous effects. Doctors and patients also found the cosmetic result following the intraoperative boost with the ZEISS INTRABEAM System to be very good.3,4

Treatment

Comparison of EBRT and TARGIT Boost treatment duration thumbnail
Comparison of EBRT and TARGIT Boost treatment duration thumbnail

The treatment with the TARGIT Boost method shows an improved treatment outcome and can additionally reduce traditional postoperative radiotherapy by 5-8 days.2

Comparison of EBRT and TARGIT Boost recurrence rate thumbnail
Comparison of EBRT and TARGIT Boost recurrence rate thumbnail

Comparison of the breast cancer recurrence rate (Non-randomised). With the ZEISS INTRABEAM System the recurrence rate is only half of the recurrence rate of conventional radiotherapy.1

This method has over 14 years of clinical experience. Clinical results reveal that the recurrence rate is only approximately a low 1.7 percent in the first five years after surgery.1


Related Topics

TARGIT-A

TARGIT-A
INTRABEAM 600

INTRABEAM 600
Applications

Oncological Indications
TARGIT Academy

TARGIT Academy

* The ZEISS INTRABEAM System consists of: INTRABEAM PRS 500 with XRS 4, INTRABEAM Cart and NC32 INTRABEAM Floor Stand 

  • 1 Vaidya, J. S., Baum, M., Tobias, J. S., Wenz, F., Massarut, S., Keshtgar, M., … Joseph, D. (2011). Long-Term Results of Targeted Intraoperative Radiotherapy (Targit) Boost During Breast-Conserving Surgery. International Journal of Radiation Oncology*Biology*Physics, 81(4), 1091–1097.
  • 2 Wenz, F., Welzel, G., Blank, E., Hermann, B., Steil, V., Sütterlin, M., & Kraus-Tiefenbacher, U. (2010). Intraoperative Radiotherapy as a Boost During Breast-Conserving Surgery Using Low-Kilovoltage X-Rays: The First 5 Years of Experience With a Novel Approach. International Journal of Radiation Oncology*Biology*Physics, 77(5), 1309–1314.
  • 3 Kraus-Tiefenbacher, U., Bauer, L., Kehrer, T., Hermann, B., Melchert, F., & Wenz, F. (2006). Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity. Oncology Research and Treatment, 29(3), 77–82.
  • 4 Kraus-Tiefenbacher, U., Bauer, L., Scheda, A., Fleckenstein, K., Keller, A., Herskind, C., … Wenz, F. (2006). Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery. International Journal of Radiation Oncology*Biology*Physics, 66(2), 377–381.